These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 3131033

  • 1. The effect of fluosol-DA and oxygenation status on the activity of cyclophosphamide in vivo.
    Teicher BA, Herman TS, Holden SA, Cathcart KN.
    Cancer Chemother Pharmacol; 1988; 21(4):286-91. PubMed ID: 3131033
    [Abstract] [Full Text] [Related]

  • 2. Effect of fluosol-DA/carbogen on etoposide/alkylating agent antitumor activity.
    Teicher BA, Bernal SD, Holden SA, Cathcart KN.
    Cancer Chemother Pharmacol; 1988; 21(4):281-5. PubMed ID: 3131032
    [Abstract] [Full Text] [Related]

  • 3. Effect of various oxygenation conditions and fluosol-DA on cytotoxicity and antitumor activity of bleomycin in mice.
    Teicher BA, Holden SA, Cathcart KN, Herman TS.
    J Natl Cancer Inst; 1988 Jun 15; 80(8):599-603. PubMed ID: 2453675
    [Abstract] [Full Text] [Related]

  • 4. Effects of various oxygenation conditions on the enhancement by Fluosol-DA of melphalan antitumor activity.
    Teicher BA, Crawford JM, Holden SA, Cathcart KN.
    Cancer Res; 1987 Oct 01; 47(19):5036-41. PubMed ID: 3113727
    [Abstract] [Full Text] [Related]

  • 5. Approaches to defining the mechanism of enhancement by Fluosol-DA 20% with carbogen of melphalan antitumor activity.
    Teicher BA, Holden SA, Jacobs JL.
    Cancer Res; 1987 Jan 15; 47(2):513-8. PubMed ID: 3098413
    [Abstract] [Full Text] [Related]

  • 6. Differential enhancement of melphalan cytotoxicity in tumor and normal tissue by Fluosol-DA and oxygen breathing.
    Teicher BA, Holden SA, Rose CM.
    Int J Cancer; 1985 Nov 15; 36(5):585-9. PubMed ID: 3932225
    [Abstract] [Full Text] [Related]

  • 7. Modification of photodynamic therapy-induced hypoxia by fluosol-DA (20%) and carbogen breathing in mice.
    Fingar VH, Mang TS, Henderson BW.
    Cancer Res; 1988 Jun 15; 48(12):3350-4. PubMed ID: 3130983
    [Abstract] [Full Text] [Related]

  • 8. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
    Teicher BA, Herman TS, Tanaka J, Eder JP, Holden SA, Bubley G, Coleman CN, Frei E.
    Cancer Res; 1991 Feb 15; 51(4):1086-91. PubMed ID: 1825474
    [Abstract] [Full Text] [Related]

  • 9. The influence of Fluosol-DA and carbogen breathing on the antitumor effects of cyclophosphamide in vivo.
    Kim GE, Song CW.
    Cancer Chemother Pharmacol; 1989 Feb 15; 25(2):99-102. PubMed ID: 2513138
    [Abstract] [Full Text] [Related]

  • 10. Effect of Fluosol-DA/O2 on tumor-cell and bone-marrow cytotoxicity of nitrosoureas in mice bearing FSA-II fibrosarcoma.
    Teicher BA, Holden SA, Rose CM.
    Int J Cancer; 1986 Aug 15; 38(2):285-8. PubMed ID: 3089945
    [Abstract] [Full Text] [Related]

  • 11. Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma.
    Teicher BA, Herman TS, Tanaka J, Dezube B, Pardee A, Frei E.
    Cancer Chemother Pharmacol; 1991 Aug 15; 28(1):45-50. PubMed ID: 1904012
    [Abstract] [Full Text] [Related]

  • 12. Effects of Fluosol-DA and oxygen breathing on adriamycin antitumor activity and cardiac toxicity in mice.
    Teicher BA, Holden SA, Crawford JM.
    Cancer; 1988 Jun 01; 61(11):2196-201. PubMed ID: 3365649
    [Abstract] [Full Text] [Related]

  • 13. Addition of a hypoxic cell selective cytotoxic agent (mitomycin C or porfiromycin) to Fluosol-DA/carbogen/radiation.
    Holden SA, Herman TS, Teicher BA.
    Radiother Oncol; 1990 May 01; 18(1):59-70. PubMed ID: 2113698
    [Abstract] [Full Text] [Related]

  • 14. Survey of the effect of adding Fluosol-DA 20%/O2 to treatment with various chemotherapeutic agents.
    Teicher BA, Holden SA.
    Cancer Treat Rep; 1987 Feb 01; 71(2):173-7. PubMed ID: 3100035
    [Abstract] [Full Text] [Related]

  • 15. Effect of various oxygenation conditions and fluosol-DA on cancer chemotherapeutic agents.
    Teicher BA, McIntosh-Lowe NL, Rose CM.
    Biomater Artif Cells Artif Organs; 1988 Feb 01; 16(1-3):533-46. PubMed ID: 2460166
    [Abstract] [Full Text] [Related]

  • 16. Addition of misonidazole, etanidazole, or hyperthermia to treatment with fluosol-DA/carbogen/radiation.
    Teicher BA, Herman TS, Holden SA, Jones SM.
    J Natl Cancer Inst; 1989 Jun 21; 81(12):929-34. PubMed ID: 2525198
    [Abstract] [Full Text] [Related]

  • 17. Effect of oxygen on the cytotoxicity and antitumor activity of etoposide.
    Teicher BA, Holden SA, Rose CM.
    J Natl Cancer Inst; 1985 Dec 21; 75(6):1129-33. PubMed ID: 3934448
    [Abstract] [Full Text] [Related]

  • 18. Evidence for macrophage involvement in the enhancement of tumor growth delay with X-ray/Fluosol-DAR/O2 combination therapy.
    Holden SA, Teicher BA, McIntosh NL, Rose CM.
    Anticancer Res; 1987 Dec 21; 7(3 Pt B):385-90. PubMed ID: 3115174
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic effect of infused Fluosol-DA/carbogen with ephedrine, flunarizine, or nitroprusside.
    Teicher BA, Holden SA, Northey D, Dewhirst MW, Herman TS.
    Int J Radiat Oncol Biol Phys; 1993 Apr 30; 26(1):103-9. PubMed ID: 8482616
    [Abstract] [Full Text] [Related]

  • 20. Nicotinamide, Fluosol DA and Carbogen: a strategy to reoxygenate acutely and chronically hypoxic cells in vivo.
    Chaplin DJ, Horsman MR, Aoki DS.
    Br J Cancer; 1991 Jan 30; 63(1):109-13. PubMed ID: 1846549
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.